Alemtuzumab: Validation of a sensitive and simple enzyme-linked immunosorbent assay

Leukemia Research

Volumn 28, Issue 12, 2004, Pages 1255-1262

  Jilani, Iman ^a   Keating, Michael ^b   Giles, Francis J ^b   O'Brien, Susan ^b   Kantarjian, Hagop M ^b   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; CLL; ELISA; Humanized; MabCampath

Indexed keywords

ALEMTUZUMAB; ANTILEUKEMIC AGENT;

ANTIGEN RECOGNITION; ARTICLE; BLOOD SAMPLING; CHRONIC LYMPHATIC LEUKEMIA; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SCREENING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; LOW TEMPERATURE; PRIORITY JOURNAL; ROOM TEMPERATURE; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; STORAGE; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BLOOD PRESERVATION; CRYOPRESERVATION; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; REFERENCE STANDARDS;

EID: 4744371910     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.04.003     Document Type: Article

References (24)

1. Hale G., Bright S., Chumbley G., Hoang T., Metcalf D., Munro A.J., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood. 62:1983;873-882
2. Hale G., Swirsky D., Waldmann H., Chan L.C. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone-marrow transplantation. Br. J. Haematol. 60:1985;41-48
3. Gilleece M.H., Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 82:1993;807-812
4. Kirchhoff C. CD52 is the 'major maturation-associated' sperm membrane antigen. Mol Hum Reprod. 2:1996;9-17
5. Focarelli R., Francavilla S., Francavilla F., Della Giovampaola C., Santucci A., Rosati F. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa. Mol. Hum. Reprod. 5:1999;46-51
6. Treumann A., Lifely M.R., Schneider P., Ferguson M.A. Primary structure of CD52. J. Biol. Chem. 270:1995;6088-6099
7. Hale G. The CD52 antigen and development of the Campath antibodies. Cytotherapy. 3:2001;137-143
8. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J.C., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 99:2002;3554-3561
9. Pawson R., Dyer M.J., Barge R., Matutes E., Thornton P.D., Emmett E., et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. 15:1997a;2667-2672
10. Pawson R., Matutes E., Brito-Babapulle V., Maljaie H., Hedges M., Mercieca J., et al. Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia? Leukemia. 11:1997;1009-1013
11. Ferrajoli A., O'Brien S., Kurzock R., Giles F., Williams M., Thomas D., et al. Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD52. Proc. Am. Soc. Clin. Oncol. 19:2000;8a. Abstract 22
12. Hale G., Jacobs P., Wood L., Fibbe W.E., Barge R., Novitzky N., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 26:2000;69-76
13. Kottaridis P.D., Milligan D.W., Chopra R., Chakraverty R.K., Chakbarti S., Robinson S., et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 96:2000;2419-2425
14. Chakraverty R., Peggs K., Chopra R., Milligan D.W., Kottaridis P.D., Verfuerth S., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 99:2002;1071-1078
15. Lim S.H., Hale G., Marcus R.E., Waldmann H., Baglin T.P. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol. 84:1993;542-544
16. Lockwood C.M., Thiru S., Isaacs J.D., Hale G., Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 341:1993;1620-1622
17. Lockwood C.M., Thiru S., Stewart S., Hale G., Isaacs J., Wraight P., et al. Treatment of refractory Wegeners's granulomatosis with humanized monoclonal antibodies. QJM. 89:1996;903-912
18. Killick S.B., Marsh J.C., Hale G., Waldmann H., Kelly S.J., Gordon-Smith E.C. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br. J. Haematol. 97:1997;306-308
19. Rebello P., Cwynarski K., Varughese M., Eades A., Apperley J.F., Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy. 3:2001;261-267
20. Rebello P., Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J. Immunol. Methods. 260:2002;285-302
21. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 332:1988;323-327
22. Keating M., O'Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Sem. Oncol. 27:2000;86-90
23. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19:2001;2153-2164
24. Manshouri T, Giles F, O'Brien S, Cortes J, Thomas D, Kantarjian H, Keating MJ. Soluble CD52 is detectable in the plasma of patients with chronic lymphocytic leukemia, Blood 149a, 2001. Abstract 629.